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immunogenicity met all licensure criteria, clinical efﬁcacy
was demonstrated and safety proﬁle was comparable to egg
derived vaccines1.14th International Congress on Infectious Diseases (ICID) Abs
with permanent sequelae such as cognitive or neuropsy-
chiatric complaints, dysphasia, hearing defects and spinal
paralysis. The severity of the disease and the lack of causal
therapy emphasize the need for prevention of tick borne
encephalitis (TBE) by vaccination. Inactivated, whole virus
TBE vaccines (FSME IMMUN, Baxter and Encepur, Novartis)
are widely used in Europe. In recent years a full clini-
cal development program, including safety, immunogenicity
and seropersistence studies has been conducted for FSME-
IMMUN in all age groups. Antigen doses of 2.4g and 1.2g
were identiﬁed as optimal for adults and children, respec-
tively. In an ongoing study, the safety and immunogenicity of
FSME-IMMUN 0.25ml Junior and Encepur 0.25ml Children are
being investigated in children 1 to 11 years of age. A total of
150 and 152 subjects were enrolled in the FSMEIMMUN and
Encepur group, respectively. Immunogenicity was assessed
by two different ELISA assays using antigens homologous to
the TBEV strains of either FSME IMMUN (IMMUNOZYM1), or
Encepur (Enzygnost2). Four weeks after the second vacci-
nation, in the FSME-IMMUN group, 100% of subjects were
seropositive in both the IMMUNOZYM- (>126 VIEU/ml) and
the Enzygnost ELISA (>10.32U/ml) compared with 94.0%
and 96.7% respectively, in the Encepur group. Geometric
mean concentrations (GMC) measured by IMMUNOZYM ELISA
were 3026 in the FSME-IMMUN and 678 in the Encepurgroup.
GMCs measured with the Enzygnost ELISA were 163.3 (FSME-
IMMUN) and 93.7 (Encepur). Local reactions after the 1st
vaccination occurred in 12.7% with FSME-IMMUN and in 28.9%
with Encepur. The rate of systemic reactions was compara-
ble: 9.3% (FSME-IMMUN) and 11.8% (Encepur). The presently
marketed TBE vaccines represent highly effective tools for
the prevention of this continuously spreading disease.
doi:10.1016/j.ijid.2010.02.1862
37.003
Strategies for the Development of New Vaccines
S.A. Plotkin
University of Pennsylvania and Vaxconsult, Doylestown, PA,
USA
The reputation of vaccination rests on a two hundred
year old history of success against major infectious dis-
eases. In general, two achievements have been crucial to the
success of vaccines: the induction of long-lasting immuno-
logical memory in individuals and the stimulation of a herd
immunity that enhances control of infectious diseases in
populations. However, when one reviews the vaccines now
available it is apparent that most successes have been
obtained when the microbe has a bacteremic or viremic
phase during which it is susceptible to the action of neu-
tralizing antibodies, and before replication in the particular
organ to which it is tropic.Success has also been achieved against some agents repli-
cating on respiratory or gastrointestinal mucosae, against
which it has been possible to induce immune responses act-
ing locally as well as systemically.
1 IMMUNOZYM FSME IgG, Progen.
2 Enzygnost TBE, Dade Behring.
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Control of intracellular pathogens has not been achieved,
xcept partly with the BCG vaccine against tuberculosis,
nd modern efforts are directed towards pathogens against
hich cellular immune responses are critical.
Newer approaches in vaccine production such as nucleic
cid immunization, vectors, reverse genetics and additional
outes of administration may circumvent prior difﬁculties.
he target of vaccination will shift towards adolescents,
dults, patients in hospital and those with chronic diseases
nd possibly will extend to therapy as well as prevention.
he major scientiﬁc problems to be solved are maintenance
f immune memory, immaturity and post-maturity of the
mmune system, and adjuvants capable of stimulating selec-
ive cell types.
oi:10.1016/j.ijid.2010.02.1863
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The Vero cell line is the most widely accepted contin-
ous cell line by regulatory authorities and has been used
ince decades for the production of, e.g. polio-, rabies- and
otavirus vaccines. Here we report on the clinical charac-
erization of Vero cell derived inactivated pandemic- and
easonal inﬂuenza vaccines.
A whole virus H5N1vaccine based on (Viet-
am/1203/2004/H5N1, clade 1) was demonstrated to
e safe and had an excellent tolerability proﬁle. A dose
f 7.5 $g of a non-adjuvanted vaccine formulation was
ighly immunogenic and induced antibodies neutralizing
omologous strains as well as viruses from other H5N1
lades. A booster dose of a heterologous (clade 2) H5N1
accine 12-17 months later resulted in enhanced antibody
esponses against both the original (clade 1) and the booster
clade 2) strain, indicative of .cross-protective memory.
A vaccine against the current pandemic H1N1 strain is
eing studied in adults and children. In adults, two doses of
.5$g antigen induced seroprotective HA antibody titers in
9% - 91% of subjects. An ongoing pediatric study demon-
trated that after the second dose 100% seroprotection (HI
ssay) was attained in the 3-8 and 9-17 year old cohorts.
Vero cell derived trivalent seasonal inﬂuenza vaccines
split virion), using wildtype virus seed stocks were devel-
ped and extensively tested in human studies. Their1 This Project has been funded in whole with Federal (United
tates Government) funds from the Ofﬁce of the Assistant Secre-
ary for Preparedness and Response, Ofﬁce of Biomdical Advanced
esearch and Development Authority, under contract NUMBER
HS0100200600013C to DynPort Vaccine Company LLC, a CSC
ompany, under No.:S1008307 awarded to Baxter Healthcare Cor-
oration.
